Of interest, inhibition of SHP2 activity diminished skin lesions, increased life span, reduced lupus-associated organ damage, blocked abnormal T cell proliferation, normalized extracellular signal regulated kinase ERK/MAPK signaling, and decreased production of IFN-γ and IL-17A/F in lupus-prone mice. This evidence concerns the gene IFNG and systemic lupus erythematosus.